Showing results (101-110 of 109) with videos related to
Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 109 results.
Breast Cancer (Tokyo, Japan)|March 3, 2024
Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice GuidelinesMasaya Hattori, Naoko Honma, Shigenori Nagai, et al.Breast Cancer (Tokyo, Japan)|December 11, 2023
Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress ScaleYosuke Aoyama, Eri Hoshino, Akihiko Shimomura, et al.Journal for Immunotherapy of Cancer|September 14, 2023
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)Jun Masuda, Hitomi Sakai, Junji Tsurutani, et al.Intensive Care Medicine|September 1, 2025
A reappraisal of association between ventilator-associated events and mortality among critically ill patients using marginal structural model: multicenter observational studySusumu Nakahashi, Kei Suzuki, Takaya Nakashima, et al.Neurology|January 17, 2014
Genotype-phenotype correlations in alternating hemiplegia of childhoodMasayuki Sasaki, Atsushi Ishii, Yoshiaki Saito, et al.Breast Cancer (Tokyo, Japan)|June 24, 2026
Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trialTakashi Yamanaka, Joohyuk Sohn, Kazuki Sudo, et al.Endocrine-Related Cancer|September 1, 2025
Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancerTakayuki Ueno, Louis W C Chow, Wonshik Han, et al.NPJ Breast Cancer|August 22, 2024
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancerEmi Noguchi, Takashi Yamanaka, Hirofumi Mukai, et al.Breast Cancer (Tokyo, Japan)|October 7, 2023
The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 editionMitsuo Terada, Aki Ito, Yuichiro Kikawa, et al.Pageof 11